-+ 0.00%
-+ 0.00%
-+ 0.00%

OSE Immunotherapeutics Announces 2026–2028 Strategic Plan Focusing on Tedopi Phase 3 Completion, New Indications and Formulations for Lusvertikimab, and Expansion of Strategic Partnerships

Reuters·12/09/2025 06:30:11

Please log in to view news